Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications
Mitochondrial and Cytosolic One-Carbon Metabolism Is a Targetable Metabolic Vulnerability in Cisplatin-Resistant Ovarian Cancer.
Journal: Molecular cancer therapeutics
Published: August 28, 2023
Correction: Novel Pyrrolo[3,2-d]Pyrimidine Compounds Target Mitochondrial and Cytosolic One-Carbon Metabolism with Broad-spectrum Antitumor Efficacy.
Journal: Molecular cancer therapeutics
Published: January 05, 2023
Therapeutic Targeting of Mitochondrial One-Carbon Metabolism in Cancer.
Journal: Molecular cancer therapeutics
Published: May 18, 2020
Design, synthesis and biological evaluation of novel pyrrolo[2,3-d]pyrimidine as tumor-targeting agents with selectivity for tumor uptake by high affinity folate receptors over the reduced folate carrier.
Journal: Bioorganic & medicinal chemistry
Published: December 16, 2019
Cellular Pharmacodynamics of a Novel Pyrrolo[3,2-d]pyrimidine Inhibitor Targeting Mitochondrial and Cytosolic One-Carbon Metabolism.
Journal: Molecular pharmacology
Published: July 24, 2019
Discovery of amide-bridged pyrrolo[2,3-d]pyrimidines as tumor targeted classical antifolates with selective uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.
Journal: Bioorganic & medicinal chemistry
Published: July 01, 2019
Novel Pyrrolo[3,2-d]pyrimidine Compounds Target Mitochondrial and Cytosolic One-carbon Metabolism with Broad-spectrum Antitumor Efficacy.
Journal: Molecular cancer therapeutics
Published: January 09, 2019
Showing 1-7 of 7
Last Updated: 09/26/2026